{"id":"W2538251152","doi":"10.1200/jco.2009.27.15_suppl.3023","title":"Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sorafenib; Temsirolimus; Sunitinib; Internal medicine; Oncology; Bevacizumab; Everolimus; Adverse effect; Phases of clinical research; Vascular endothelial growth factor; Progression-free survival; Renal cell carcinoma; Gastroenterology; Clinical trial; Overall survival; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; VEGF receptors","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001693183,0.001586822,0.002323968,0.0004458249,0.0004840246,0.001002681,0.001039454,0.00123214,0.003400619],"category_scores_gemma":[0.0007035027,0.0005985934,0.001325844,0.0003678617,0.0008849904,0.0006026338,0.0003804258,0.002896193,0.001145246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001097058,"about_ca_system_score_gemma":0.002640833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001464361,"about_ca_topic_score_gemma":0.003298487,"domain_scores_codex":[0.9995626,0.0001681376,0.00002358678,0.00007635386,0.0000520276,0.0001173078],"domain_scores_gemma":[0.9992852,0.00007373551,0.0001057267,0.00006163031,0.00005753469,0.0004162318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.599777,0.1588036,0.009645012,0.001181718,0.002098833,0.001035337,0.0005656136,0.004457613,0.1223012,0.000331831,0.007389226,0.09241292],"study_design_scores_gemma":[0.4600341,0.5160576,0.009404086,0.0000282488,0.0004292127,0.000601274,0.00005809001,0.001152418,0.009022836,0.000135667,0.003042718,0.00003378541],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868724,0.002167288,0.001086683,0.0004364816,0.000144776,0.00648604,0.001314679,0.0001242535,0.001367404],"genre_scores_gemma":[0.9850524,0.001414641,0.002800888,0.0006419152,0.0001382183,0.004764766,0.002761438,0.00003899992,0.002386687],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003400619,"threshold_uncertainty_score":0.0113762,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2761104646616537,"score_gpt":0.5126640576467328,"score_spread":0.2365535929850791,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}